

**Electrocardiographic Parameters and Fatal Arrhythmic Events in Patients with
Brugada Syndrome: Combination of Depolarization and Repolarization
Abnormalities.**

Koji Tokioka†, MD, Kengo F. Kusano§, MD, PhD, Hiroshi Morita†, MD, PhD, Daiji
Miura†, PhD, Nobuhiro Nishii†, MD, PhD, Satoshi Nagase†, MD, PhD, Kazufumi
Nakamura†, MD, PhD, Kunihisa Kohno†, MD, PhD, Hiroshi Ito†, MD, PhD, Tohru Ohe‡,
MD, PhD

† Department of Cardiovascular Medicine, Okayama University Graduate School of
Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

§ Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center,
Osaka, Japan

‡ The Sakakibara Heart Institute of Okayama, Okayama, Japan

Conflict of interest: None declared

Address for Correspondence

Kengo F. Kusano

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center,
5-7-1 Fujishiro-dai, Suita, Osaka 5658565, Japan

Tel: +81-6-6833-5012

Fax: +81-6-6872-7486

Email: kusanokengo@hotmail.com

Abbreviated title: ECG markers in high-risk Brugada syndrome

Abstract

Objectives: This study aimed to determine the usefulness of the combination of several electrocardiographic (ECG) markers on risk assessment of ventricular fibrillation (VF) in patients with Brugada syndrome (BrS).

Background: Detection of high/low-risk BrS patients using a noninvasive method is an important issue in the clinical setting. Several ECG markers related to depolarization and repolarization abnormalities have been reported, but the relationship and usefulness of these parameters in VF events are unclear.

Methods: Baseline characteristics of 246 consecutive patients (236 males; mean age, 47.6 ± 13.6 years) with Brugada type ECG, including 13 patients with a history of VF and 40 patients with a history of syncope episodes, were retrospectively analyzed. During the mean follow-up period of 45.1 months, VF in 23 patients and sudden cardiac death (SCD) in one patient were observed. Clinical/genetic and electrocardiographic parameters were compared with VF/SCD events.

Results: By univariate analysis, history of VF, history of syncope episodes, paroxysmal atrial fibrillation, spontaneous type 1 pattern in the precordial leads, ECG markers of depolarization abnormalities (PQ > 200 ms, QRS duration ≥ 120 ms, and fragmented QRS [f-QRS]), and those of repolarization abnormalities (infero-lateral early repolarization [ER] pattern and QT prolongation) were associated with later cardiac events. By multivariable analysis, history of VF, history of syncope episodes, infero-lateral ER pattern, f-QRS were independent predictors of documented VF and SCD (odds ratio, 19.61, 28.57, 2.87, and 5.21, respectively, $P < 0.05$). Kaplan-Meier curves showed that the presence/absence of infero-lateral ER and f-QRS provided a worse/better prognosis (log-rank test, $P < 0.01$).

Conclusions: The combination of depolarization and repolarization abnormalities in BrS is associated with later VF events. The combination of these abnormalities is useful for detecting high- and low-risk BrS patients.

Keywords: Brugada syndrome, fragmented QRS, early repolarization, ventricular fibrillation, noninvasive risk assessment

Abbreviations:

BrS: Brugada syndrome

ECG: electrocardiogram

EP: electrophysiology

ER: early repolarization

f-QRS: fragmented QRS

ICD: implantable cardioverter defibrillator

PAF: paroxysmal atrial fibrillation

SCD: sudden cardiac death

SCN5A: pore-forming region of the human cardiac sodium channel

VF: ventricular fibrillation

Introduction

Brugada syndrome (BrS) is a distinct form of idiopathic ventricular fibrillation (VF). BrS is characterized by a unique electrocardiogram (ECG) pattern consisting of a right bundle branch block-like morphology and ST-segment elevation in precordial leads. Results of many studies (1-10) have suggested that patients with syncope, particularly patients with a spontaneous type 1 ECG pattern, have a significant risk of sudden cardiac death (SCD) or VF. In the remaining population of asymptomatic subjects, the risk is lower, but not negligible (1,5). Therefore, assessment of the risk of SCD and VF in patients with Brugada type ECG is clinically important, especially when sporadic cases are detected during routine medical check-ups.

Many markers for development of VF in BrS have been reported, including clinical markers of a family history of sudden cardiac death (11), syncope with nonprodromal episodes (12), episodes of paroxysmal atrial fibrillation (PAF) (13), electrocardiographic markers of spontaneous type 1 ECG pattern, existence of late potential (14), fragmented QRS (f-QRS) (15), T-wave alternans after sodium channel blocker injection (16), an infero-lateral early repolarization (ER) pattern (17,18), a genetic marker of *SCN5A*, a gene encoding the cardiac sodium channel (19), electrophysiological markers of VF inducibility by programmed electrical stimulation, abnormal restitution properties, and ventricular effective refractory period <200ms (20). However, the relationship of these markers and the usefulness of their combination have not been sufficiently examined.

In this study, we examined risk markers, with a focus on noninvasive surface ECG markers categorized by depolarization and repolarization abnormalities, and attempted to improve the accuracy of prediction and classification of high- and low-risk

BrS patients.

Methods

Patient population and clinical data collection

We retrospectively analyzed data from 246 consecutive patients (236 males; mean age, 47.6 ± 13.6 years) with Brugada type ECG in Okayama University Hospital. All patients showed a typical ECG “Brugada pattern” with or without a sodium channel blocker (pilsicainide), which was defined previously (11). Informed consent was obtained from all subjects, and clinical data, including data on age, sex, family history of SCD (less than 45 years old), history of syncopal episodes, history of VF episodes, and VF induction during electrophysiological (EP) study were obtained from patient records. Follow-up data defined that the start of follow-up was taken as first visit, and the end of follow-up was set to death, arrhythmic events, or the last visit.

Electrocardiographic measurements

Standard 12-lead ECGs were recorded in the same way and were evaluated for the RR interval, PQ interval, QRS width, QT interval, ST level at the J point, and number of positive spikes within the QRS complex in leads V1 through V3. A spontaneous type 1 pattern was defined as documentation by ECG of a type 1 pattern in the absence of class I anti-arrhythmic drugs. The presence of a late potential was evaluated by a signal-averaged ECG (ART 1200 EPX, noise level $< 0.3 \mu\text{V}$, and high-pass filtering of 40 Hz with a bidirectional 4-pole Butterworth). A late potential was positive when the following two criteria were met: root-mean-square voltage of the terminal 40 ms in the filtered QRS complex $< 20 \mu\text{V}$ and a duration of low-amplitude signals $< 40 \mu\text{V}$ in the terminal filtered QRS complex $> 38 \text{ms}$ (21).

The presence of f-QRS was defined as an abnormal fragmentation within the QRS complex as \geq four spikes in one or \geq eight spikes in all of the leads V1, V2, and V3 as described previously(15)(Figure 1A).

An infero-lateral ER pattern was defined as an elevation of the J point in at least two consecutive leads. The amplitude of the J wave or J-point elevation had to be at least 1 mm above the baseline level, either as QRS slurring or notching in the inferior lead (II, III, and aVF), lateral (I, aVL, and V4–V6) lead, or both as described previously(17,18,22-25)(Figure 1B).

We divided the patients into the depolarization abnormality (PQ interval >200 ms, QRS width ≥ 120 ms, positive late potential, and f-QRS) group and the repolarization abnormality (QT prolongation and infero-lateral ER pattern) group.

EP study

After obtaining written informed consent from patients, an EP study was performed as described previously(1,26) in all patients. The criterion for the induction of ventricular arrhythmia was induction of sustained polymorphic ventricular tachycardia or VF by programmed electrical stimulation from the right ventricular apex, right ventricular outflow tract, or left ventricle with a maximum of three extrastimuli at two cycle lengths.

Gene mutation analysis of *SCN5A*

This study was performed in compliance with guidelines for human genome studies of the Ethics Committee of Okayama University as described previously(13). In brief, all exons of *SCN5A* were amplified by polymerase chain reaction from DNA isolated from peripheral leukocytes of the patients. Genomic DNA was extracted from peripheral blood leukocytes using a DNA extraction kit (Gentra, Minneapolis, Minnesota, USA)

and was stored at -30°C until use. Twenty-seven exons of the *SCN5A* gene were amplified with previously reported intronic primers(13).

Statistical analysis

Statistical analysis was performed using SPSS 17.0 for Windows (SPSS Inc, Chicago, IL, USA). Data are expressed as mean \pm SD or median (IQR) values. Student's t test was performed to test for statistical differences between two unpaired mean values, and categorical data and percentage frequencies were analyzed by the chi-square test. In univariate analysis, nine predictors were significantly associated with arrhythmic events. Multivariate analysis using Cox proportional-hazards regression analysis estimated those nine predictors and was performed in search of independent risk factors for arrhythmic events. This analysis was based on a stepwise algorithm, with the p value set at 0.05 for entering and 0.1 for exclusion. The effects of ER and f-QRS on arrhythmic events during the follow-up period were evaluated using the log-rank test and were described using a Kaplan Meier curve. $P < 0.05$ was considered statistically significant.

Results

Patients' characteristics

Baseline patients' characteristics are summarized in Table 1. Sixty-nine patients (28.0%) had a family history of SCD, 40 (16.3%) had history of syncope episodes, and 13 (5.3%) had history of VF episodes. Gene analysis showed that *SCN5A* gene mutation was present in 17 patients (13.8%). Spontaneous type I ECG was observed in 156 patients (63.4%). In the EP study, VF was induced in 71 patients (45.8%), and 63 of them (25.6%) had received ICD implantation. During the follow-up period of 45.1 ± 44.3 months, fatal arrhythmic events occurred in 24 patients (23 appropriate ICD

shocks due to VF and one cardiac arrest during sleep).

Clinical/genetic/ECG parameters and cardiac events

Clinical and genetic parameters were compared in BrS patients with and those without cardiac events during the follow-up period (Table 2). PAF episodes (9/24, 37.5% versus 35/222, 15.8%, $P=0.013$), a history of VF (9/24, 37.5% versus 4/222, 1.8%, $P<0.001$), a history of syncopal episodes (13/24, 54.2% versus 27/222, 12.2%, $P<0.001$), VF inducibility during EP study (17/24, 70.8% versus 54/131, 41.2%, $P=0.007$), and spontaneous type 1 ECG (22/24, 91.7% versus 134/222, 60.4%, $P=0.002$) were observed more often in VF/SCD patients than in those without VF/SCD, but other parameters such as age, sex, family history of SCD, and *SCN5A* gene mutation were not different.

Among the ECG parameters of depolarization abnormalities, QRS width ≥ 120 ms (8/24, 33.3% versus 29/222, 13.1%, $P=0.015$), and f-QRS (20/24, 83.3% versus 58/222, 26.1%, $P<0.001$) were observed more often in patients with VF/SCD than in those without VF/SCD. Among the ECG parameters of repolarization abnormalities, a prolonged QTc interval >440 ms (7/24, 29.2% versus 28/222, 12.6%, $P=0.036$) and infero-lateral ER pattern (8/24, 33.3% versus 17/222, 7.7%, $P<0.001$) were observed more often in patients with VF/SCD than in those without VF/SCD.

Multivariate analysis showed that the following four parameters were independent risk factors for arrhythmic events: f-QRS (hazard ratio, 5.21; 95% confidence interval [CI], 1.69 to 16.13; $P=0.004$), infero-lateral ER pattern (hazard ratio, 2.87; 95% CI, 1.16 to 7.14; $P=0.023$), a history of VF episodes (hazard ratio, 19.61; 95% CI, 4.12 to 90.91; $P<0.001$), and a history of syncopal episodes (hazard ratio, 28.57; 95% CI, 6.14 to 142.86; $P<0.001$) (Table 2).

Patients' characteristics with f-QRS

In multivariate analysis, depolarization abnormalities of f-QRS were an independent risk factor for arrhythmic events. Therefore, clinical, genetic, and electrocardiographic data for patients with and those without f-QRS were analyzed again (Table 3). There were no significant differences in age, family history of SCD, and incidence of the *SCN5A* gene mutation between patients with and those without f-QRS. However, a history of syncope, a history of VF episodes, and VF inducibility during EP study were more frequently observed in patients with f-QRS than in those without f-QRS ($P=0.002$, 0.005 , and 0.002 , respectively). PQ interval, QRS duration and QTc interval were longer in patients with f-QRS than in those without f-QRS ($P=0.037$, 0.001 , and 0.042 , respectively), but the ER pattern was not different between the groups. Spontaneous type I ECG and PAF episodes were more frequently observed in patients with f-QRS than in those without f-QRS ($P<0.001$ and $P=0.031$, respectively). VF/SCD episodes during follow-up were more frequently observed in patients with f-QRS than in those without f-QRS ($P<0.001$).

Patients' characteristics with an ER pattern

In multivariate analysis, repolarization abnormality of the ER pattern was an independent risk factor for arrhythmic events. Therefore, clinical, genetic, and electrocardiographic data with and without an ER pattern were analyzed again (Table 4). There were no significant differences in age, family history of SCD, incidence of *SCN5A* gene mutation, positive late potential, a history of syncope, f-QRS, and VF inducibility during the EP study. However, VF/SCD episodes during follow-up and a

history of VF episodes were more frequently observed in patients with ER than in those without ER ($P=0.001$ and 0.005 , respectively).

Follow-up data

We next examined the follow-up data in patients with f-QRS and ER. Twenty-three patients developed VF, one patient died suddenly during sleep, possibly due to VF, and one patient died of a non-arrhythmic cause (pneumonia) during the follow-up period.

Figure 2 shows the results of Kaplan-Meier analyses of fatal arrhythmic events in patients with and those without f-QRS (Fig. 2A) or an ER (Fig. 2B) pattern. Patients with f-QRS or ER had a significantly worse prognosis than did patients without those parameters ($P<0.001$ and <0.001 , respectively).

Figure 3 shows results of the combination analysis of f-QRS and ER parameters. Patients with both f-QRS and ER parameters had a significantly higher frequency of fatal arrhythmic events than did patients without both parameters ($P<0.001$). Moreover, patients with both f-QRS and ER parameters had a significantly higher frequency of arrhythmic events than did patients with f-QRS alone ($P=0.045$, Fig. 3).

Discussion

The present study showed that the combination of f-QRS and infero-lateral ER pattern was associated with development of VF in BrS patients. Additionally, the combination of f-QRS with ER (depolarization and repolarization abnormalities) was useful for identifying high- and low-risk BrS patients.

High-risk clinical parameters of VF development

Previous studies have reported that syncopal episodes (especially in patients with

prodrome), a history of VF, and a family history of sudden death are associated with VF events in BrS patients(3,4,12,20,27-29). In our study, we also observed that syncopal episodes and a history of VF were independent predictors of later VF events. These patients were symptomatic patients, and therefore it is reasonable to classify them as high-risk patients. However, more patients have no symptoms with electrocardiographic evidence of Brugada syndrome (asymptomatic Brugada patients). A recent study suggested that these asymptomatic patients have a better prognosis, but not negligible (1,5). Therefore, simple risk assessment for these asymptomatic Brugada patients is clinically important, especially when sporadic cases are detected during routine medical check-ups.

Repolarization abnormalities in BrS

Many clinical data support the importance of repolarization abnormalities for VF development, such as T-wave alternans after sodium channel blocker injection (16), and ST elevation after exercise (30) or full-stomach status(31) .

An ER pattern is considered to be a benign ECG phenomenon affecting 2–5% of the general population and is most commonly observed in young men (32,33). Recently, an ER pattern has been shown as an additional risk marker for VF development, especially in infero-lateral leads, in patients with BrS(17,18). Our finding that repolarization abnormalities were independently associated with VF development is in agreement with these previous findings.

Depolarization abnormalities in BrS

In addition to repolarization abnormalities, recent observations have suggested that VF development in BrS is associated with conduction disturbances, such as prolongation of the PQ interval (34), a wide QRS complex (35), a positive late potential (36), and

f-QRS (15,20). A recent study showed that f-QRS is the strongest predictor of VF development in BrS(20). The usefulness of f-QRS for identifying patients at high risk for various cardiac diseases, including cardiac sarcoidosis, arrhythmogenic right ventricular cardiomyopathy, and acute coronary syndrome (37), has been reported. Our finding that f-QRS (depolarization abnormality) was an independent predictor for VF development is in agreement with those results. We also found that f-QRS was associated with other depolarization abnormalities, such as a prolonged PQ and QRS interval, indicating that depolarization abnormalities in the atrium and ventricle are an important factor for development of VF in BrS.

A QRS interval in lead V2 ≥ 120 ms was found to be a possible predictor of life-threatening ventricular arrhythmia and/or syncope. Prolonged QRS duration as measured on a standard 12-lead ECG has been shown to be associated with ventricular arrhythmia (35). Additionally, a prolonged QRS duration in precordial leads is prominent in symptomatic patients, suggesting that delayed conduction of the ventricle (depolarization) is important (29,38). However, in multivariate analysis in our study, there were no significant differences in wide QRS complex between patients with and those without VF/SCD.

Combination of depolarization and repolarization abnormalities

In this study, Kaplan-Mayer analyses showed that the combination of f-QRS (depolarization abnormality) and ER (repolarization abnormality) is useful for predicting VF events in patients with BrS. Recently, f-QRS was reported to be an important marker for the development of VF (Torsade de pointes) in patients with acquired long QT syndrome (typical repolarization abnormality disease) (39), indicating that the combination of depolarization and repolarization is important for the

development of lethal arrhythmia. We also found that VF seldom developed in patients without any abnormalities during the follow-up period in this study, suggesting that low-risk BrS patients could also be identified using these markers.

We also investigated the clinical/electrocardiographic characteristics of depolarization and repolarization abnormalities. Interestingly, there were many differences between the groups (Tables 34). Patients with f-QRS had more depolarization abnormalities than those without f-QRS, such as prolonged PQ and QRS intervals. In contrast, patients with an ER pattern had no differences in these markers, suggesting that the genesis of each of these abnormalities is intrinsically different.

Clinical implications

BrS is a heterogeneous disease. Therefore, the mechanism of VF development differs in each patient. Our results suggest that the combination of depolarization and repolarization abnormalities (f-QRS, and ER pattern) enables identification of high- and low-risk patients with BrS. In the clinical setting, VF induction during EP study is still considerable to decide the ICD implantation. Thus we think we should recommend EP study in a patient with f-QRS and ER pattern even in an asymptomatic case, or we do not need EP study in an asymptomatic case of neither f-QRS nor ER pattern.

Limitations

This study has several limitations. First, the ECG features of ER and other ECG markers are dynamic, and thus the true prevalence of this coexistence is difficult to evaluate. Second, we analyzed only the coding regions of *SCN5A* for mutations in this study, and the possibility of mutations occurring in regions of the gene other than

coding regions or other gene mutations cannot be excluded. Third, Nishii et al. reported that *SCN5A* gene mutations are associated with early and frequent VF recurrence(19), but not with initial VF episodes. In our study, we did not find a significant difference. Therefore, further studies on this issue are required. Fourth, this study was a retrospective study. A prospective study to estimate risk factors of BrS is required. And the last, there were a small number of endpoints making it difficult to identify unique predictors in a multivariate model reliably.

Conclusions

Our study shows that ER and f-QRS are independent risk factors for arrhythmic events in patients with BrS. Patients with both ER and f-QRS have a significantly higher frequency of arrhythmic events than do patients who have neither ER nor f-QRS. Furthermore, when there is neither ER nor f-QRS, arrhythmic events are small.

Clinically, this study shows that the combination of f-QRS (marker of depolarization abnormality) and ER (marker of repolarization abnormality) is useful for estimating the incidence of VF in patients with BrS.

References

1. Brugada J, Brugada R, Brugada P. Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. *Circulation* 2003;108:3092-6.
2. Brugada P, Brugada R, Mont L, Rivero M, Geelen P, Brugada J. Natural history of Brugada syndrome: the prognostic value of programmed electrical stimulation of the heart. *J Cardiovasc Electrophysiol* 2003;14:455-7.
3. Priori SG, Napolitano C, Gasparini M et al. Natural history of Brugada syndrome: insights for risk stratification and management. *Circulation* 2002;105:1342-7.
4. Eckardt L, Probst V, Smits JP et al. Long-term prognosis of individuals with right

- precordial ST-segment-elevation Brugada syndrome. *Circulation* 2005;111:257-63.
5. Brugada P, Brugada R, Brugada J. Should patients with an asymptomatic Brugada electrocardiogram undergo pharmacological and electrophysiological testing? *Circulation* 2005;112:279-92; discussion 279-92.
 6. Giustetto C, Drago S, Demarchi PG et al. Risk stratification of the patients with Brugada type electrocardiogram: a community-based prospective study. *Europace* 2009;11:507-13.
 7. Tsuji H, Sato T, Morisaki K, Iwasaka T. Prognosis of subjects with Brugada-type electrocardiogram in a population of middle-aged Japanese diagnosed during a health examination. *Am J Cardiol* 2008;102:584-7.
 8. Benito B, Sarkozy A, Mont L et al. Gender differences in clinical manifestations of Brugada syndrome. *J Am Coll Cardiol* 2008;52:1567-73.
 9. Sidik NP, Quay CN, Loh FC, Chen LY. Prevalence of Brugada sign and syndrome in patients presenting with arrhythmic symptoms at a Heart Rhythm Clinic in Singapore. *Europace* 2009;11:650-6.
 10. Sarkozy A, Boussy T, Kourgiannides G et al. Long-term follow-up of primary prophylactic implantable cardioverter-defibrillator therapy in Brugada syndrome. *Eur Heart J* 2007;28:334-44.
 11. Antzelevitch C, Brugada P, Borggreffe M et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. *Circulation* 2005;111:659-70.
 12. Take Y, Morita H, Toh N et al. Identification of high-risk syncope related to ventricular fibrillation in patients with Brugada syndrome. *Heart Rhythm* 2012;9:752-9.
 13. Kusano KF, Taniyama M, Nakamura K et al. Atrial fibrillation in patients with Brugada syndrome relationships of gene mutation, electrophysiology, and clinical backgrounds. *J Am Coll Cardiol* 2008;51:1169-75.
 14. Nagase S, Kusano KF, Morita H et al. Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome: using the epicardial lead. *J Am Coll Cardiol* 2002;39:1992-5.
 15. Morita H, Kusano KF, Miura D et al. Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. *Circulation* 2008;118:1697-704.
 16. Tada T, Kusano KF, Nagase S et al. Clinical significance of macroscopic T-wave alternans after sodium channel blocker administration in patients with Brugada syndrome. *J Cardiovasc Electrophysiol* 2008;19:56-61.

17. Sarkozy A, Chierchia GB, Paparella G et al. Inferior and lateral electrocardiographic repolarization abnormalities in Brugada syndrome. *Circ Arrhythm Electrophysiol* 2009;2:154-61.
18. Kamakura S, Ohe T, Nakazawa K et al. Long-term prognosis of probands with Brugada-pattern ST-elevation in leads V1-V3. *Circ Arrhythm Electrophysiol* 2009;2:495-503.
19. Nishii N, Ogawa M, Morita H et al. SCN5A mutation is associated with early and frequent recurrence of ventricular fibrillation in patients with Brugada syndrome. *Circ J* 2010;74:2572-8.
20. Priori SG, Gasparini M, Napolitano C et al. Risk stratification in Brugada syndrome: results of the PRELUDE (PRogrammed ELectrical stimUlation preDICTive valuE) registry. *J Am Coll Cardiol* 2012;59:37-45.
21. Morita H, Takenaka-Morita S, Fukushima-Kusano K et al. Risk stratification for asymptomatic patients with Brugada syndrome. *Circ J* 2003;67:312-6.
22. Tikkanen JT, Anttonen O, Junttila MJ et al. Long-term outcome associated with early repolarization on electrocardiography. *N Engl J Med* 2009;361:2529-37.
23. Haïssaguerre M, Derval N, Sacher F et al. Sudden cardiac arrest associated with early repolarization. *N Engl J Med* 2008;358:2016-23.
24. Tikkanen JT, Junttila MJ, Anttonen O et al. Early repolarization: electrocardiographic phenotypes associated with favorable long-term outcome. *Circulation* 2011;123:2666-73.
25. Letsas KP, Sacher F, Probst V et al. Prevalence of early repolarization pattern in inferolateral leads in patients with Brugada syndrome. *Heart Rhythm* 2008;5:1685-9.
26. Brugada P, Geelen P, Brugada R, Mont L, Brugada J. Prognostic value of electrophysiologic investigations in Brugada syndrome. *J Cardiovasc Electrophysiol* 2001;12:1004-7.
27. Brugada J, Brugada R, Antzelevitch C, Towbin J, Nademanee K, Brugada P. Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. *Circulation* 2002;105:73-8.
28. Atarashi H, Ogawa S, Harumi K et al. Three-year follow-up of patients with right bundle branch block and ST segment elevation in the right precordial leads: Japanese Registry of Brugada Syndrome. Idiopathic Ventricular Fibrillation Investigators. *J Am Coll Cardiol* 2001;37:1916-20.
29. Takagi M, Yokoyama Y, Aonuma K, Aihara N, Hiraoka M, Investigators JIVFSJ-I.

- Clinical characteristics and risk stratification in symptomatic and asymptomatic patients with brugada syndrome: multicenter study in Japan. *J Cardiovasc Electrophysiol* 2007;18:1244-51.
30. Makimoto H, Nakagawa E, Takaki H et al. Augmented ST-segment elevation during recovery from exercise predicts cardiac events in patients with Brugada syndrome. *J Am Coll Cardiol* 2010;56:1576-84.
 31. Ikeda T, Abe A, Yusu S et al. The full stomach test as a novel diagnostic technique for identifying patients at risk of Brugada syndrome. *J Cardiovasc Electrophysiol* 2006;17:602-7.
 32. Shu J, Zhu T, Yang L, Cui C, Yan GX. ST-segment elevation in the early repolarization syndrome, idiopathic ventricular fibrillation, and the Brugada syndrome: cellular and clinical linkage. *J Electrocardiol* 2005;38:26-32.
 33. Gussak I, Antzelevitch C. Early repolarization syndrome: clinical characteristics and possible cellular and ionic mechanisms. *J Electrocardiol* 2000;33:299-309.
 34. Miyamoto A, Hayashi H, Makiyama T et al. Risk determinants in individuals with a spontaneous type 1 Brugada ECG. *Circ J* 2011;75:844-51.
 35. Ohkubo K, Watanabe I, Okumura Y et al. Prolonged QRS duration in lead V2 and risk of life-threatening ventricular Arrhythmia in patients with Brugada syndrome. *Int Heart J* 2011;52:98-102.
 36. Ajiro Y, Hagiwara N, Kasanuki H. Assessment of markers for identifying patients at risk for life-threatening arrhythmic events in Brugada syndrome. *J Cardiovasc Electrophysiol* 2005;16:45-51.
 37. Naruse Y, Tada H, Harimura Y et al. Early repolarization is an independent predictor of occurrences of ventricular fibrillation in the very early phase of acute myocardial infarction. *Circ Arrhythm Electrophysiol* 2012;5:506-13.
 38. Atarashi H, Ogawa S, Investigators IVF. New ECG criteria for high-risk Brugada syndrome. *Circ J* 2003;67:8-10.
 39. Haraoka K, Morita H, Saito Y et al. Fragmented QRS is associated with torsades de pointes in patients with acquired long QT syndrome. *Heart Rhythm* 2010;7:1808-14.

Figure legends

Figure1: Representative ECGs of fragmented QRS (f-QRS) and early repolarization

(ER). (A) Fragmented QRS (f-QRS) was observed in lead V2. Note that there are four

spikes (arrows) in this lead. (B) Early repolarization (ER) pattern in the inferior leads.




Note that J-point elevation above the baseline ($>1\text{mm}$) can be seen in leads III and aVF.


Figure2: Kaplan-Meier analysis of VF/SCD events.

Ventricular fibrillation (VF)/ sudden cardiac death (SCD) events were observed often in the presence of (A) fragmented QRS (f-QRS), and (B) early repolarization (ER).

Figure3: Kaplan-Meier analysis of VF/SCD events.


Ventricular fibrillation (VF)/ sudden cardiac death (SCD) events were observed often in the combination of depolarization (f-QRS) and repolarization abnormalities (ER pattern).






N. of patients

	0	20	40	60	80	100
f-QRS neg.	168	93	62	46	28	14
f-QRS pos.	78	43	35	23	12	5



N. of patients

	0	20	40	60	80	100
ER neg.	221	121	87	60	32	14
ER pos.	25	15	10	9	8	5



N. of patients

Neither	152	83	55	39	22	11
fQRS pos.	78	43	35	23	12	5
ER pos.	25	15	10	9	8	5
Both	9	5	3	2	2	2

Table1 . Patients' Characteristics

Male/Female		236/10
Age, yrs		47.6±13.6
Mean follow up period, months		45.1±44.3
History of syncopal episode (%)	40	(16.3%)
History of VF episode (%)	13	(5.3%)
Family history of SCD (%)	69	(28.0%)
Paroxysmal AF (%)	44	(17.9%)
Spontaneous type-1 ECG (%)	156	(63.4%)
ER pattern (%)	25	(10.2%)
fragmented QRS (%)	78	(31.7%)
Positive LP (%)	166/235	(70.6%)
SCN5A gene mutation (%)	17/123	(13.8%)
VF induction during EP study (%)	71/155	(45.8%)
ICD implantation (%)	63	(25.6%)
VF or SCD event during follow-up period (%)	24	(9.8%)

Values are mean ±SD or number of patients.

AF=atrial fibrillation; ECG=electrocardiogram; EP=electrophysiology;

ER=early repolarization; ICD=implantable cardioverter defibrillator;

LP=late potential; SCD=sudden cardiac death;

SCN5A =pore-forming region of the human cardiac sodium channel;

and VF=ventricular fibrillation.

Table 2. Characteristics of patients with and without VF/SCD during follow-up | Univariate Analysis

	VF/SCD (+)	VF/SCD(-)	Odds Ratio	95%CI
Clinical/genetic parameters				
Number of patients (male/female)	23/1	213/9	1.029	0.125-8.490
Age, yrs	47 (15)	48 (21)		
History of syncopal episode (%)	13 (54.2)	27 (12.2)	8.535	3.477-20.955
History of VF episode (%)	9 (37.5)	4 (1.8)	32.700	.012-118.645
Paroxysmal AF (%)	9 (37.5)	35 (15.8)	3.206	1.301-7.899
Family history of SCD (%)	8 (33.3)	61 (27.5)	1.320	0.537-3.241
SCN5A gene mutation (%)	4/23 (17.4)	3/100 (3.0)	1.409	0.414-4.799
VF induction during EP study	17/24 (70.8)	54/131 (41.2)	3.463	1.344-8.293
Spontaneous type-1 ECG (%)	22 (91.7)	134 (60.4)	7.224	1.657-31.491
Depolarization parameters				
Positive f-QRS (%)	20 (83.3)	58 (26.1)	14.138	4.638-43.093
Positive LP (%)	20/24 (83.3)	46/211 (69.2)	2.226	0.732-6.772
PQ >200msec (%)	8 (33.3)	40 (18.0)	2.275	0.911-5.681
QRS \geq 120msec (%)	8 (33.3)	29 (13.1)	3.328	1.307-8.469
Repolarization parameters				
ER pattern (%)	8 (33.3)	17 (7.7)	6.029	2.258-16.103
QTc >440msec (%)	7 (29.2)	28 (12.6)	2.853	1.087-7.490

Values are mean \pm SD, median (IQR), or number of patients.

AF=atrial fibrillation; CI=confidence interval; ECG=electrocardiogram; EP=electrophysiology; ER=late potential; SCN5A =pore-forming region of the human cardiac sodium channel; VF=ventricular fibrillation

period				
is				
Multivariate Analysis				
p Value	Hazard Ratio	95%CI	p Value	
0.649				
0.835				
<0.001	28.571	5.135-142.857	<0.001	
<0.001	19.608	4.115-90.909	<0.001	
0.013			0.306	
0.554				
0.396				
0.007			0.562	
0.002			0.114	
<0.001	5.208	1.689-16.129	0.004	
0.150				
0.069				
0.015			0.908	
<0.001	2.874	1.160-7.143	0.023	
0.036			0.608	

=early repolarization; f-QRS = fragmented QRS;
ular fibrillation.

Table3. Characteristics of patients with and without f-QRS

	f-QRS(+)	f-QRS(-)
Clinical/genetic parameters		
Number of patients (male/female)	76/2	160/8
Age, yrs	48.5± 12.9	47.2±14.0
History of syncopal episode (%)	21 (26.9)	19 (11.3)
History of VF episode (%)	9 (11.5)	4 (2.4)
Paroxysmal AF (%)	20 (25.6)	24 (14.3)
Family history of SCD (%)	23 (29.5)	46 (27.4)
SCN5A gene mutation (%)	9/43 (20.9)	8/80 (10.0)
VF induction during EP study (%)	34/54 (63.0)	37/101 (35.9)
ICD implantation (%)	37 (47.4)	26 (15.5)
VF or SCD event during follow-up (%)	20 (25.6)	4 (2.4)
ECG parameters		
Duration of PQ interval, msec	184±29	176±26
Duration of QRS complex, msec	108 (24)	100 (17)
Duration of QTc interval, msec	419±30	411±24
Amplitude at J point V1, mV	0.12 (0.15)	0.11 (0.10)
Amplitude at J point V2, mV	0.21 (0.21)	0.201 (0.17)
Amplitude at J point V3, mV	0.13 (0.12)	0.12 (0.12)
Positive ER pattern (%)	9 (11.5)	16 (9.5)
Spontaneous type-1 ECG (%)	63 (80.8)	93 (55.4)
Positive LP (%)	59/75 (78.7)	107/160(66.9)

Values are mean ±SD, median (IQR), or number of patients.

AF=atrial fibrillation; ECG=electrocardiogram; EP=electrophysiology; ER=early repolarization; f-QRS=fragmented QRS; ICD=implantable cardioverter defibrillator; LP=late potentials; SCD=sudden cardiac death; SCN5A=pore-forming region of the human cardiac sodium channel; VF=ventricular fibrillation

p Value

0.511
0.514
0.002
0.005
0.031
0.732
0.094
0.002
<0.001
<0.001

0.037
0.001
0.042
0.347
0.468
0.929
0.653
<0.001
0.064

olarization;
al;
m channel;

Table4. Characteristics of patients with and without ER

	ER(+)	ER(-)
Clinical/genetic parameters		
Number of patients, men/women	23/2	213/8
Age, yrs	43 (23)	49 (20)
History of syncopal episode (%)	5 (20.0)	35 (15.8)
History of VF episode (%)	5 (20.0)	8 (3.6)
Paroxysmal AF (%)	3 (12.0)	41 (18.6)
Family history of SCD (%)	7 (28.0)	62 (28.1)
SCN5A gene mutation (%)	2/15 (13.3)	15/108 (13.9)
VF induction during EP study (%)	9/21 (42.9)	62/134 (46.3)
ICD implantation (%)	13 (52.0)	50 (22.6)
VF or SCD event during follow-up (%)	8 (32.0)	16 (7.2)
ECG parameters		
Duration of PQ interval, msec	190±34	177±26
Duration of QRS complex, msec	99 (17)	104 (20)
Duration of QTc interval, msec	405±27	414±26
Amplitude at J point V1, mV	0.14 (0.14)	0.11 (0.12)
Amplitude at J point V2, mV	0.21 (0.25)	0.20 (0.16)
Amplitude at J point V3, mV	0.17 (0.17)	0.12 (0.11)
Positive f-QRS (%)	9 (36.0)	69 (31.2)
Spontaneous type 1 ECG (%)	14 (56.0)	142 (64.3)
Positive LP (%)	17/23 (73.9)	149/212 (70.3)

Values are mean ±SD, median (IQR), or number of patients.

AF=atrial fibrillation; ECG=electrocardiogram; EP=electrophysiology; ER=early repolar
f-QRS=fragmented QRS; ICD=implantable cardioverter defibrillator; LP=late potential;
SCD=sudden cardiac death;
SCN5A=pore-forming region of the human cardiac sodium channel; VF=ventricular fibrillation

p Value

0.269
0.820
0.383
0.005
0.584
0.995
1.000
0.770
0.001
0.001

0.053
0.335
0.097
0.306
0.505
0.069
0.653
0.417
0.717

ization;

illation